Professional Documents
Culture Documents
RTAG0152305
Record ID
5149547683624863429
Result ID
Test Pro le: This COVID-19 Antigen Test (“RD-Ag”) is a rapid chromatographic immunoassay for the qualitative detection of speci c
antigens to SARS-CoV-2 (COVID-19) present in human nasopharynx. This test is approved for designated and limited uses by the World
Health Organization and or The US Food and Drug Administration ("FDA"), and is also CE marked (CE marking is an administrative marking
that indicates conformity with health, safety, and environmental protection standards for products sold within the European Economic
Area).
The test used is either a STANDARD Q or ABBOTT'S PANBIO, both of which are on an approved list for limited use in The Bahamas, as
designated by The Ministry of Health.
Important Disclosure: The RD-Ag test performed is used for screening purposes only and is not validated for the de nitive diagnosis for
SARS-COV-2 (COVID-19) in a comparable fashion as a real-time polymerase chain reaction (RT-PCR)-test. This screening report is not a
RT-PCR COVID19 test result. RD-Ag tests are most likely to perform well in patients with high viral loads (Ct values ≤25 or >106 genomic
virus copies/mL) which usually appear in the pre-symptomatic (1-3 days before symptom onset) and early symptomatic phases of the
illness (within the rst 5-7 days). A negative result does not preclude SARS-CoV-2 infection and should not be used as the sole basis for
patient management and workplace planning decisions. When diagnostic testing is negative, the possibility of a false negative result
should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with
COVID-19.